- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04776811
Evaluation of Accuracy of Guardian Sensor 3 in Diabetes Patients on Peritoneal Dialysis
November 24, 2022 updated by: Elaine Chow
Assessment of performance (precision and accuracy) of Guardian Sensor™ 3 as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
None Selected
-
Hong Kong, None Selected, China
- Elaine Chow
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Diabetes patients on continuous ambulatory peritoneal dialysis
Description
Inclusion Criteria:
- Type 1 or 2 diabetes mellitus diagnosed for at least 3 months
- On continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months
- Male or female age ≥ 18 years old and ≤ 75 year old.
- Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
- Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
- Willingness to abstain from swimming during their participation in the measurement phase.
- In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
- Written informed consent to participate in the study provided by the patient.
Exclusion Criteria:
- Poorly controlled diabetes mellitus with HbA1c>11%
- Peritonitis within 1 month
- On icodextrin PD solutions
- Planned for switching to hemodialysis or living donor transplant in future 3 months
- Currently pregnant, as demonstrated by a positive pregnancy test at screening
- Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
- Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
- Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
- Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).
- Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.
- Blood donation of more than 500 ml within the last three months
- Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
13 Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.
14. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
15. Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period 16. Patients with history of pacemaker and prosthesis implantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean absolute relative difference (MARD)
Time Frame: 5 minutes
|
MARD of sensor versus YSI glucose
|
5 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median absolute relative difference (MedARD)
Time Frame: 5 minutes
|
MedARD of sensor versus YSI glucose
|
5 minutes
|
Consensus Error grid analysis
Time Frame: 5 minutes
|
% sensor values in regions A and B
|
5 minutes
|
Percent accuracy
Time Frame: 5 minutes
|
System readings within 15%, 20%, 30%, 40% and greater than 40% of YSI values
|
5 minutes
|
Hypoglycemia detection rates
Time Frame: 15 minutes
|
True and false hypoglycemia notification rate, correct and missed hypoglycemia detection rate
|
15 minutes
|
Hyperglycemia detection rates
Time Frame: 15 minutes
|
True and false hyperglycemia notification rate, correct and missed hyperglycemia detection rates
|
15 minutes
|
User satisfaction
Time Frame: 2 weeks
|
Diabetes Satisfaction Treatment Questionnaire score
|
2 weeks
|
Correlation between CGM metrics, HbA1c and fructosamine
Time Frame: 2 weeks
|
Correlation between CGM metrics, HbA1c and fructosamine
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elaine Chow, PhD, MBChB, Chinese University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2021
Primary Completion (Actual)
September 30, 2022
Study Completion (Actual)
September 30, 2022
Study Registration Dates
First Submitted
February 27, 2021
First Submitted That Met QC Criteria
February 27, 2021
First Posted (Actual)
March 2, 2021
Study Record Updates
Last Update Posted (Actual)
November 28, 2022
Last Update Submitted That Met QC Criteria
November 24, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PDGS3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
University of KansasCompletedEnd-Stage Renal Disease
-
Eisai Co., Ltd.CompletedEnd-Stage Renal DiseaseJapan
Clinical Trials on Continuous glucose monitoring system
-
Senseonics, Inc.CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1United States
-
Charles University, Czech RepublicUnknown
-
Kinderkrankenhaus auf der BultSenseonics, Inc.Completed
-
Charles University, Czech RepublicUnknownDiabetes Mellitus, Type 1Czechia
-
Ningbo No. 1 HospitalNot yet recruitingType 2 Diabetes Mellitus | Acute Coronary SyndromeChina
-
Institut für Diabetes-Technologie Forschungs- und...CompletedSubjects Without Diabetes Mellitus | Assessment of Glucose ConcentrationsGermany
-
Pusan National University HospitalCompletedGlucose Metabolism Disorders | Diabetes Mellitus | PreDiabetesKorea, Republic of
-
University of Wisconsin, MadisonWithdrawn
-
Senseonics, Inc.UnknownDiabetes MellitusCanada
-
DexCom, Inc.UnknownDiabetes MellitusUnited States